Frequency Therapeutics Announces New FX-322 Results

Frequency Therapeutics, Inc announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved “statistically significant hearing improvements when evaluated 8 to 12 months following initial dosing.”